window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Central Nervous System

  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Al-S Pharma presents Phase 2 AP-101 data supporting misfolded SOD1 target in ALS at ENCALS 2026

    Al-S Pharma reports Phase 2 AP-101 data in ALS showing [...]

    June 25, 2026
  • Advanced Therapies,Biotech & Pharma Business,Central Nervous System,Drug Discovery & Development

    TRIMTECH raises $14M to advance protein degradation therapies for neurodegenerative diseases

    TRIMTECH Therapeutics has secured an additional $14 million in seed [...]

    June 23, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development

    CONNECTA starts Phase 2a trial of CTH120 for fragile X syndrome

    CONNECTA Therapeutics has started a Phase 2a clinical trial of [...]

    June 10, 2026
  • Biotech & Pharma Business,Central Nervous System,Drug Discovery & Development

    Deep Science Ventures and Medicines Discovery Catapult target blood-brain barrier challenge

    Deep Science Ventures and Medicines Discovery Catapult have launched a [...]

    June 6, 2026
  • Central Nervous System,Digital & Data,Drug Delivery & Formulation,Drug Discovery & Development,Therapeutic Areas

    Bonito Biosciences partners with DaltonTx on AI-driven RNA delivery research

    Bonito Biosciences has entered a collaboration with DaltonTx to develop [...]

    June 6, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome

    Emalex Biosciences has secured a US patent for an orally [...]

    May 5, 2026
  • Central Nervous System,Drug Discovery & Development,Therapeutic Areas

    Strategies to extend ketamine antidepressant effects identified in new study

    Researchers have identified a molecular target that could extend the [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    International Brain Health Conference 2026 to focus on early intervention before dementia

    The inaugural International Brain Health Conference 2026 in Edinburgh will [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Lario receives $2.4M from MJFF and Wellcome to expand neuronal calcium channel research in CNS disorders

    Lario Therapeutics awarded $2.4M by The Michael J. Fox Foundation [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory

    Newron secures up to EUR 38 million to advance Phase 3 evenamide program in treatment-resistant schizophrenia

    Newron Pharmaceuticals has secured up to EUR 38 million in [...]

    May 5, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Polaryx advances Phase 2 trial of PLX-200 in four rare diseases
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Lumen Bioscience gets up to $7M to advance LMN-1001 into Phase 1
    Categories: Advanced Therapies, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development
  • Brainomix to present five ILD studies on quantitative CT at ERS Congress
    Categories: Advanced Therapies, Clinical & Regulatory, Digital & Data, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top